Press releases

7 Mar 2025

BIMZELX[®] (bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden

27 Feb 2025

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

12 Feb 2025

BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS)

10 Feb 2025

UCB Advances Long-Term Innovation Strategy with New Research & Development Facility at Braine-l’Alleud Campus

31 Jan 2025

RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods

15 Jan 2025

UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation

Press releases

Press releases

Search Press releases

BIMZELX[®] (bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS)

UCB Advances Long-Term Innovation Strategy with New Research & Development Facility at Braine-l’Alleud Campus

RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods

UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our 2026...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2025 - Direct access to our latest annual report

UCB Community Health Fund enters a new phase

UCBCares® - Discover what UCBCares® is about and the services they offer

BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study...

Strong Execution Fueling Sustained Company Growth

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment...

Strong Execution Fueling Sustained Company Growth

Innovation and Execution Power UCB’s Success

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

BIMZELX[®] (bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS)

UCB Advances Long-Term Innovation Strategy with New Research & Development Facility at Braine-l’Alleud Campus

RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods

UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation

Choose a Country